Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines

Summary

To evaluate the safety and efficacy of EB-001 compared to placebo in subjects with glabellar frown lines (GL).

Timeline

Start

2016-12

Primary completion

2017-07-12

Completion

2017-07-12

Publications

• Yoelin SG, Dhawan SS, Vitarella D, Ahmad W, Hasan F, Abushakra S. Safety and Efficacy of EB-001, a Novel Type E Botulinum Toxin, in Subjects with Glabellar Frown Lines: Results of a Phase 2, Randomized, Placebo-Controlled, Ascending-Dose Study. Plast Reconstr Surg. 2018 Dec;142(6):847e-855e. doi: 10.1097/PRS.0000000000005029.

Drugs

Indications

No indication recorded.